Traws Pharma Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Ratutrelvir (COVID): Positive final Phase 2a results support further studies in PAXLOVID®-ineligible
Ratutrelvir (COVID): Positive final Phase 2a results support further studies in PAXLOVID®-ineligible